Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 in support of researchers with a novel approach to pediatric oncology investigation. This can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of successfully competing for extramural funding. To be eligible, applicants must possess a degree at the MD, MD/PhD or PhD level and hold a faculty appointment at an academic institution.

The Pancreatic Cancer Action Network is accepting applications for its 2018 Catalyst Grant program. The program, which aims to encourage and support junior faculty in the pursuit of pancreatic cancer research and establish a career path in the field, provides grants of up to $500,000 over three years to junior investigators who have yet to secure their first significant research funding. Research projects may be basic, translational, clinical, or epidemiological in nature but must have direct applicability and relevance to pancreatic cancer. Grant recipients not only receive financial support for their funded research but also are invited to join the network's Community for Progress, a mentorship program that works to advance the goal of increasing survival rates and improving outcomes for pancreatic cancer patients. To be eligible, applicants must have a doctoral degree (PD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equivalent) in the biomedical sciences (or in a field applicable to health science research) and not currently be a candidate for a further doctoral degree. In addition, at the start of the grant term on July 1, 2018, applicants must hold a faculty position with the title of assistant professor, instructor, research assistant professor, or the equivalent.

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

The purpose of this FOA is to invite applications that investigate aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in this system and its organs, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. However, studies with the major focus on immune mechanisms, role of lymphatics in cancer metastasis and study of lymphatic vessels in organs other than those from the digestive system will not be considered responsive.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot InitiativeSM that is intended to accelerate cancer research. The purpose of this FOA is to promote research on developing the descriptive, inferential, and graphical statistical methods for data generated in clinical trials including Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) items. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Accelerate research that can identify approaches to monitor and manage patient-reported symptoms.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

ENTELLIGENCE, in partnership with Actelion Pharmaceuticals US, supports basic science, translational, and clinical research in the field of cardiopulmonary medicine. The program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research in pulmonary hypertension. To that end, ENTELLIGENCE is accepting applications for its thirteenth annual Young Investigator grant program. Established in 2005, the program provides opportunities for promising young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, clinical, or translational) in the area of pulmonary hypertension specifically related to expanding knowledge of pulmonary vascular pathobiology pathways. In 2018, the program will award a one-year grant of up to $100,000 to fund a mentored project.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

The purpose of this FOA is to invite applications that investigate aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in this system and its organs, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. However, studies with the major focus on immune mechanisms, role of lymphatics in cancer metastasis and study of lymphatic vessels in organs other than those from the digestive system will not be considered responsive.

The McGovern Institute for Brain Research at the Massachusetts Institute of Technology was established in 2000 by Patrick J. McGovern and Lore Harp McGovern, with the goal of improving human welfare, communication, and understanding through their support for neuroscience research. The institute has announced a call for nominations for its twelfth annual Edward M. Scolnick Prize in Neuroscience. Now in its fifteenth year, the Scolnick Prize is designed to recognize outstanding advances in the field of neuroscience. The prize, which is endowed through a gift from Merck to the McGovern Institute, consists of a $150,000 award, plus an inscribed gift. In addition, the recipient will present a public lecture at the McGovern Institute in spring 2018. A gala dinner for the recipient and invited guests follows the prize lecture. Candidates for the award must be nominated by individuals affiliated with universities, hospitals, medicals schools, or research institutes, with a background in neuroscience. Self-nomination is not permitted.

Grants are made by the Board of Trustees of Ohio Cancer Research taking into account studies and recommendations of the Scientific Review Committee. Grants are available to investigators in either nonprofit or for-profit institutions, offices or clinics within the State of Ohio. However, grants to investigators working for profit-making organizations may not include funds for capital equipment. Grants are made with the stipulation of their use by a particular individual or group who are known as the principal investigator in support of a specific program of research under his/her/their direction. Full professors or their equivalent are not eligible. Only tenure track, junior faculty or equivalent scientific staffs are generally considered as appropriate. Postdoctoral fellows, Research, research assistants, and graduate students are ineligible to apply as P.I.'s, but they may be included as support staff. The P.I. must show evidence of independence. Applicants must be within six years of their first independent research or faculty appointment. Well established investigators should not submit projects related to their current area of research. Investigators previously funded by Ohio Cancer Research must provide justification that this application is significantly different from the previously funded project. Information regarding the results of the previously funded proposal and the P.I.'s success in obtaining further national funding must also be provided. Grants awarded by Ohio Cancer Research are made to support research activities broadly related to cancer and leukemia. Certain types of projects are not recommended for support. Among these are purely clinical work of a non-research nature and requests for the sole purpose of equipping a laboratory.

The United States Agency for International Development (USAID) plans to provide up to $40 million in total USAID funding over a period of five-years. The purpose of the activity is to increase utilization of FP services through universal health coverage. It will be accomplished through: 1) strengthening capacity to more effectively train medical providers and community health workers in FP in both the public and private sectors; and, 2) focusing and expanding public sector FP information and services to high need groups such as adolescents, youth, newlyweds, and postpartum girls and women. The results this activity will achieve include: 1. Increased qualified FP workforce in public and private sectors, and 2. Increased availability of public sector FP outreach contacts and services, particularly for adolescents and youth.

The purpose of the funding opportunity announcement (FOA) is to encourage research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness.

This Funding Opportunity Announcement (FOA) encourages applications to study the ethical, legal and societal issues (ELSI) of human genome research in African populations. Of particular interest are projects that propose focused bioethical, legal, and social science analyses of new or emerging issues.

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. This Funding Opportunity Announcement (FOA) will solicit research projects to facilitate the development and translation of tools and technology for non-invasive imaging and profiling of human central nervous system (CNS, including retina) small blood and lymphatic vessels; to investigate their role in CNS physiology, disease, repair processes, and responses to therapy using novel approaches. Applications can be focused on the development of new technology and tools, novel target or biomarker identification and validation studies, or a combination of mechanistic and technology development studies specific to human CNS small blood and lymphatic vessels in health and disease, across the life span.

The American Psychological Foundation provides financial support for innovative research and programs that enhance the power of psychology to elevate the human condition and advance human potential, both today and for generations to come. As part of this mission, APF is accepting applications for its APF Trauma Psychology Grant. Through the annual program, a single grant of up to $3,000 will be awarded in support innovative work aimed at alleviating trauma. To be eligible, applicants must be an early-career psychologist (no more than ten years postdoctoral); be affiliated with a nonprofit charitable, educational, or scientific institution, or governmental entity operating exclusively for charitable and educational purposes; have a demonstrated knowledge of trauma and trauma research; have demonstrated competence and capacity to execute the proposed work; and, if human participants are involved, have IRB approval from his/her host institution before funding can be awarded.

The When Everyone Survives Foundation was founded to advance cures and treatment for leukemia through support for innovative research. To that end, the foundation has issued its 2018 Request for Proposals for leukemia research. One-year grants of up to $50,000 will be awarded in support of innovative laboratory, translational, or clinical research related to acute leukemia. Renewal of initial research support may be considered for one or more additional years based on productivity. New and established investigators are eligible to apply.

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research supports public early detection screening for ovarian cancer, produces nationally and internationally attended research symposia, and provides funding for innovative ovarian cancer research and scholar grants to up-and-coming investigators. The center is accepting applications for pilot study projects in ovarian cancer research. Through the center's Pilot Study Program, approximately ten one-year grants of $75,000 will be awarded to support investigator-initiated projects in all areas of ovarian cancer research. Projects designed to analyze data from already funded clinical trials also will be considered. Priority will be given to proposals that are innovative, multi-disciplinary, and likely to lead to the submission of grant applications for independently funded investigations. Investigators at all levels are encouraged to apply.

The American Association for Cancer Research is accepting applications for its AACR NextGen Grants for Transformative Cancer Research program. The annual program is designed to stimulate highly innovative research from young investigators. Three-year grants of up to $450,000 will be awarded in support of creative, paradigm-shifting cancer research that might not be funded through conventional channels. The funds are intended to support expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies and equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; and other research expenses and indirect costs. Research projects must represent a highly innovative approach to a major contemporary challenge in cancer research. The research, which can be in any area of basic, translational or clinical science, must have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or ability to treat, detect, or prevent cancer. To be eligible, applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. In addition, at the start of the grant term on July 1, 2018, applicants must hold a tenure-eligible appointment at the level of assistant professor; have held this appointment for no more than three years; and work at an academic, medical, or research institution anywhere in the world. AACR membership is required.